Precision Health AI’s Brigham Hyde Explains How Company Is Bringing Insight to Treating Cancer

Precision Health AI’s Brigham Hyde Explains How Company Is Bringing Insight to Treating Cancer

EPISODE 117

Brigham Hyde, CEO of Precision Health AI, explains the company is building out a data platform for oncology treatment. The firm is building products to serve pharma, life science companies, providers, and payers. In this podcast, Hyde explains how Precision Health AI can help oncologists determine stage of cancer and identify adverse effects.

Podcast Guest

Brigham_Hyde

Brigham Hyde, PhD

CEO

Precision Health AI

Dr. Brigham Hyde, PhD is the Founder and CEO of Precision Health AI. Hyde is a Research Affiliate at MIT and an Adjunct Professor and Lecturer at Tufts University Sackler School of Biomedical Science in the Department of Pharmacology. He has experience in preclinical drug development from CRO Wolfe Laboratories Inc. and has conducted research and published several articles in pharmacology and mitochondrial biology. He received his B.S. in Chemistry and a minor in Business Management from Northeastern University, as well as a Ph.D. in Pharmacology and Experimental Therapeutics from Tufts University Sackler School of Biomedical Science.

Do You Have

A STORY TO TELL?

If you’d like to be considered as a guest on a future episode of the Breaking Health podcast, please complete the application today.

Meet Our Host

STEPHEN KRUPA

Stephen Krupa

Healthegy Contributing Host Stephen Krupa is CEO of Healthedge, a software company focused on providing next-generation, business-transforming technology products to the healthcare payor market.

Subscribe

ON iTUNES

Don't miss an episode. Join the conversation by visiting our podcast channel on iTunes today and subscribe. It's fast and free!